RARE PHOTOS: Viatris inc - The Real Truth

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Benzinga · Jul 18, 2025

3 Hidden Bargains in the Healthcare Sector

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…

StockNews.com · Jan 29, 2025

3 Low P/E Stocks With Strong Growth Prospects

With easing inflation and possibilities of interest rate cuts, investors can rely on stocks like Viatris (VTRS), Open Text (OTEX), and Goodyear Tire & Rubber (GT) with strong growth prospects, trading at affordable prices. Keep reading.

StockNews.com · Jul 24, 2024

5 Pharma Stocks to Watch With Bullish Momentum

The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on.

StockNews.com · Feb 12, 2024

3 Lucrative Pharma Stocks for Portfolio Success

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

StockNews.com · Feb 2, 2024

Top 4 Pharma Picks for January 2024 Growth

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

StockNews.com · Jan 9, 2024

Under $15 Bargains: 3 Pharma Stocks to Watch

The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on….

StockNews.com · Nov 17, 2023

3 Stocks to Buy With Less Than $10

The recent collapse of two banks and growing uncertainty about the Fed’s next rate hike amid the strong economic data releases fueled a broad market sell-off lately. However, a volatile market environment offers an attractive opportunity to invest in quality stocks ADT (ADT), Viatris (VTRS), and trivago (TRVG) at reasonable…

StockNews.com · Mar 20, 2023

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

Viatris Inc (NASDAQ:VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist. Complex generics and biosimilars grew by 21% Y/Y on an operational basis, driven mainly by the generic…

Benzinga · May 9, 2022

Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label

Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is 

Benzinga · Apr 13, 2022